Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
This study provides real-world evidence of the effectiveness and safety of afatinib as first-line therapy for Chinese patients with <i>EGFR</i> mutation-positive advanced NSCLC.
Authors
- Zhiyi Xue (ORCID: https://orcid.org/0000-0002-1357-202X)
- Ke-Jing Tang
- Jianying Zhou
- Jun Wu
- Yongsheng Wang
- Yi-Long Wu
Institutions
- Sun Yat-sen University (CN)
- Sichuan University (CN)
- Zhongshan People's Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Hainan General Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Guangdong Academy of Medical Sciences (CN)
- Boehringer Ingelheim (China) (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Hainan Medical College Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Lung Cancer Targets and Therapy
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/lctt.s555262
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- BeiGene